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Abstract
Background: Hepatitis C virus (HCV) compromises Health-related Quality of Life (HRQL) with detriments to Physical,
Mental and Social health domains. Treatment with interferon and ribavirin is associated with side effects which
further impair HRQL. New treatments appear potent, effective and tolerable. However, Patient Reported Outcomes
instruments that capture the impact on HRQL for people with hepatitis C are largely non-specific and will be
needed in the new treatment era. Therefore, we developed a conceptually valid multidimensional model of
HCV-specific quality of life and pilot survey instrument, the Patient Reported Outcome Quality of Life survey
for HCV (PROQOL-HCV).
Methods: HCV patients from France (n = 30), Brazil (n = 20) and Australia (n = 20) were interviewed to
investigate HCV-HRQL issues raised in the scientific literature and by treatment specialists. Interviews were
recorded, transcribed and translated into English and French.
Results: Fifteen content dimensions were derived from the qualitative analysis, refined and fitted to four
domains: (1) Physical Health included: fatigue, pain, sleep, sexual impairment and physical activity; (2)
Mental Health: psychological distress, psychosocial impact, and cognition; (3) Social Health: support,
stigma, social activity, substance use; (4) Treatment: management, side effects, and fear of treatment
failure. The impact of some dimensions extended beyond their primary domain including: physical activity,
cognition, sleep, sexual impairment, and the three treatment dimensions. A bank of 300 items was
constructed to reflect patient reports and, following expert review, reduced to a 72-item pilot
questionnaire.
Conclusion: We present a conceptually valid multidimensional model of HCV-specific quality of life and
the pilot survey instrument, PROQOL-HCV. The model is widely inclusive of the experience of hepatitis C
and the first to include the treatment dimension.
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Background
Chronic infection with the hepatitis C virus (HCV) re-
sults in morbidity and mortality related to hepatic and
extra-hepatic disease processes. An estimated 130 and
170 million people worldwide are HCV-seropositive.
The blood-borne virus is transmitted by unsafe medical
and drug injecting practices and sexually when mucosal
integrity is breached [1]. In specific contexts, such as
prisons [2], regions with high prevalence and insufficient
prevention measures [1], and in HIV-seropositive men
[3], the risk of transmission is increased.
Anti-viral treatment can eradicate the virus, improve
hepatic histology and prevent liver-related death but
complications of chronic infection and toxicity associ-
ated with treatment can impact on health-related quality
of life (HRQL) by diminishing physical, emotional and
social functioning [4]. Second generation agents based
on a triple combination therapy (PEG-IFN + ribavirin + a
protease inhibitor: boceprevir or telaprevir) increased
HCV clearance rates but augmented toxicity and de-
creased HRQL [5]. However, enhanced HRQL through
symptom alleviation, economic and social benefits, for
example, work force participation and removal of social
stigma, can follow after successful treatment [6].
New drugs that target the virus directly are avail-
able or in clinical trial phase. These treatments, given
without concomitant interferon alpha, can result in
sustained virological response (SVR) in over 90 % of
cases. Notably, toxicity is reduced in comparison with
second generation triple combinations, although re-
sponse remains influenced by genotype, stage of fibro-
sis and pre-existing drug-resistant mutations [7, 8].
Unfortunately, the price of such drugs limits their ac-
cessibility and many people are waiting to be treated
[9]. Regardless, new therapies raise the possibility of
eradicating hepatitis C and reducing morbidity and
mortality [10].
Patient-Reported Outcome (PRO) measures are im-
portant to evaluate the impact of chronic infection;
eligibility and readiness for treatment; and assessment of
HRQL during and post treatment. These measures en-
sure patient experiences and preferences are captured in
order to discriminate between treatment options [10].
Since PRO measures provide insight into the patient’s
perspective there must be evidence that the measures re-
flect that perspective, this is content validity. A three-
tiered literature review of 74 articles by Kleinman and
colleagues [11], found 22 qualitative studies that identi-
fied chronic HCV-related concepts from which they se-
lected five on the basis that they were evidently
important to patients, easily implemented into a clinical
trial and had potential for sensitivity to change. These
five concepts were: depression/anxiety, fatigue, flu-like
symptoms, cognitive function, and insomnia [11]. Fur-
thermore the literature suggested that sexual function
[12], stigma [13], co-infection [14], resilience [15], emo-
tional volatility [16] and treatment-related impacts [17]
were important unmeasured features. In the next step,
they examined what PRO measures had been used in
clinical trials and found that these instruments provided
inadequate coverage of the concepts; and finally, that of
18 existing measures only four were validated in PRO
populations and only one demonstrated content validity
in the chronic HCV population, the Hepatitis Quality of
Life Questionnaire (HQLQ) (13).
Until recently [18, 19], there was no survey instrument
measuring, comprehensively, the HRQL of HCV patients
or included a treatment dimension. Generic measures
such as the MOS Health Survey Short-Form 36 (SF-36),
followed by the Hepatitis Quality of Life Questionnaire
(HQLQ) [20] which contributes two short HCV-specific
subscales to the SF-36 are often employed. Other HRQL
instruments used in chronic liver disease, of which HCV
is a leading cause are: The Chronic Liver Disease Ques-
tionnaire (CLDQ) [21], the Liver Disease Quality of Life
Questionnaire (LDQOL) [22], and the Liver Disease
Symptom Index 2.0 (LDSI) [23].
Ideally, HRQL instruments should be applicable
across diverse populations but most instruments were
developed in single contexts and translated into target
languages when required. These instruments are not
robust to semantic differences between languages or
cultural perceptions of health. A validated questionnaire
sensitive to these factors should offer precision in terms of
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understanding patient perspectives, monitoring clinical
impacts during treatment, and generating uniform clinical
trial data.
Aims
We aimed to develop a contemporary HCV-specific,
multidimensional, HRQL survey instrument, sensitive to
treatment, in three representative languages: English,
French and Portuguese. The development of PROQOL-
HCV was concordant with current guidelines [24, 25]
and involved a four stage process (Fig. 1): (1) devel-
opment of a conceptual model and item generation;
(2) development of a pilot questionnaire; (3) linguistic
and (4) psychometric validation. Three stages are presented
here and the psychometric validation in a second manu-




Ten experts contributed knowledge concerning current
issues relevant to HCV HRQL to build the conceptual
model; a scientific panel (physician, psychologist, nurse,
patient advocate) involved in hepatitis C management
and research conducted the qualitative analysis of inter-
views, the item generation and subsequent reduction.
An international expert panel participated in the sec-
ond step of item reduction. Professional translators
were used to achieve harmonisation between the three
languages.
Patients
Seventy patients with HCV were recruited for interview
from hospital outpatient clinics in: Australia (AU), Brazil
(BR) and France (FR). Patients were selected to reflect
the diversity of the general epidemic; were over the age
of 18 years and able to provide written informed con-
sent. The study protocol conformed to the ethical guide-
lines of the 1975 Declaration of Helsinki and was
approved by local Institutional Review Boards: CPP Ile
de France 4, Paris, France; the Royal Perth Hospital
(EC2010/103) and Murdoch University (EC2011/002)
Western Australia; and the STD/AIDS Reference and
Training Center, State in San Paulo (EC2010/010).
Fig. 1 PROQOL HCV Development process AU = Australia/English ; BR = Brazil/Portuguese ; FR = France/French
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Stage 1: Conceptual model
The first stage defined the conceptual model of
HCV HRQL and generated items to reflect this
model. Themes reflecting the lived experience of
HCV were established through literature review, spe-
cialist consultation, and particularly patient inter-
views. From patient interview syntax a bank of
potential items for a pilot PROQOL instrument was
extracted.
Patient interview guide
Medline was interrogated across the period of 1990 –
2011 to identify HCV HRQL-relevant qualitative and
quantitative research. HCV HRQL issues highlighted in
qualitative research were cross-referenced with the
content of instruments used in quantitative research to
measure HCV HRQL to identify which issues were
measured and which were not. Ten HCV experts were
likewise consulted to identify issues not covered by
existing instruments. An interview guide was subsequently
developed to explore existing and newly identified themes.
The guide comprised six open-ended questions concern-
ing the impact of HCV on activities of daily life and
seventy-three semi-structured questions spread across the
topic areas: physical, psychological and social health;
stigma; self-image and self-esteem; resilience; and
treatment.
Patient interviews
A total of seventy semi-directed interviews were con-
ducted with the patient interview guide. These were per-
formed, face to face, in English, Portuguese and French,
respectively, in 2011 (n = 20 in AU; n = 20 in BR; and 30
in FR) by experienced interviewers. A further five, in
France, explored to a greater extent the impact of new
therapies. In establishing sample size, we erred on the
side of safety and aimed for at least 20 interviews per
country to ensure thematic saturation [26]. France in-
cluded more participants to ensure inclusion of people
on the newer drugs that were at the time unavailable
outside of clinical trials in Brazil and Australia. Inter-
views of 1–2 h duration were recorded and transcribed
in the original languages.
Sample sociodemographic and clinical characteristics
are shown in Table 1. Information collected included
age, gender, ethnicity, employment status and family
living arrangements; and relevant health history, in-
cluding HCV biomarkers, symptoms and treatment
side effects measured by a self-report questionnaire
developed by Justice and colleagues [27] and adapted
by the French National Agency for Research on HIV/
AIDS and viral hepatitis (ANRS). The software pack-
age R (www.r-project.org/) was employed to generate
descriptive statistics.
Thematic analysis
Transcripts were translated into English and French by
professionals. The analysis of 70 interviews was per-
formed by the scientific panel and a qualitative approach
was taken to identify recurring themes, commonalities
and variations until data saturation was reached at 29
themes. Two pairs of Anglophone and Francophone in-
vestigators coded approximately 18,000 lines of syntax
to one or more (when concepts overlapped) emerging
themes. Differences in coding were discussed until con-
sensus was reached. Syntax were subsequently sorted and
pooled by code. Theme content was examined for dis-
tinctiveness, cross-over and redundancy. The 29 grounded
and frequently overlapping themes were refined and par-
celled into 15 broad and distinct dimensions.
Item generation
Raw statements that exemplified the content of each di-
mension were identified and converted into grammat-
ically and syntactically correct items to form a bank of
300 potential survey items in Excel, in French and
English. Each item is written with the expectation that a
respondent will indicate the extent to which it applies to
them on five point Likert scale (0 = “always”, 1 = “often”,
2 = “from time to time”, 3 = “rarely”, 4 = “never”).
Stage 2: Development of the pilot instrument
The goal was to reduce the number of items contained
in the item bank to a smaller pool representative of the
HCV HRQL dimensions identified during the interview
process. Each item was reviewed on ten criteria using a
three-point scale (1 = Yes, 2 = No, 3 = Unsure): (1) Item
content inconsistent with the theme, dimension and do-
main definitions (Item relevance); (2) Item similar in
wording (semantics) to other items (Item redundancy);
(3) Item measures general HRQL rather than HCV
HRQL (Item disease-specific); (4) Item confusing rather
than clear (Item clarity); (5) Item complex rather than
simple (Item cognitive burden); (6) Item translatability
issue; (7) Item cross-cultural fit issue; (8) Item does not
fit with a designated response category (frequency, in-
tensity, quantity); (9) Item not sensitive to change (Item
sensitivity); (10) Item less explicit than another exist-
ing item. Seventy-nine items were retained on major-
ity agreement. These 79 items were passed to the
international expert panel, who used a three-point
scale (1 = Yes, 2 = No, 3 = Unsure) to review each item
on four criteria: (1) relevance to theme, dimension
and domain definitions; (2) item clarity and comprehensi-
bility; (3) sensitivity to change; (4) and retain or delete
item. Seventy-two of the 79 items were retained on major-
ity agreement to form the pilot instrument.
It is expected that psychometric analysis and validation
of the pilot instrument will result in subscale item
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groupings based on shared content, and will reduce the
number of items to the minimum necessary to reflect
our conceptual model and adequately measure HCV
HRQL. Subscale scores based on the sum of raw item
scores will be rescaled to range from 0 to 100 for ease of
comparison.
Stage 3: Linguistic validation
English and French versions of the pilot questionnaire
underwent translatability assessment by two linguists
specialized in the development of PRO instruments.
Several items were reformulated and content speci-
fied. Forward translation into French and Portuguese
was carried out and back-translated into English.
Three draft questionnaires, in English, French and
Portuguese were compared and harmonised. Discrep-
ancies were resolved and cognitive debriefing was per-
formed on a new 20 patient sample to check concept
interpretation.
Results
The results describe the participant characteristics;
themes that emerged from participant interviews, and
the conceptual model that informed selection of items
for inclusion in the PROQOL-HCV pilot questionnaire.
Participant characteristics
Socio-demographic and clinical characteristics of the
70 interviewees are shown in Table 1. Participants
(mean age = 50 years) were predominantly male in
Australia and France, and female in Brazil. Risk ex-
posure to hepatitis C varied between countries. The
majority of Australians and half the French reported
a history of injecting drug use (IDU) in comparison
with three Brazilian patients. Fourteen patients were
co-infected with HIV. Hepatitis C virus genotype 1
was prevalent in over 60 % of cases (information on
53 patients). French patients had been diagnosed earl-
ier than the other groups but this was not thought to
Table 1 Participant characteristics by country
Variables Australia n = 20 Brazil n = 20 France n = 30 Total N = 70
Demographic factors
Male Sex 17 (85.0) 6 (30.0) 21 (70.0) 44 (62.9)
Age 48.7 (6.0) 51.8 (9.4) 50.45 (9.7) 50.3 (8.5)
Weight (kg) 83.0 (19.9) 66.8 (15.4) 70.5 (13.4) 73.0 (17.1)
Married/partner 5 (25.0) 11 (55.0) 17 (56.7) 33 (47.1)
Ethnicity Caucasian 18 (90.0) 12 (60.0) 23 (82.1) 53 (75.7)
Living alone 7 (35.0) 2 (10.0) 9 (30.0) 18 (25.7)
Living with children 4 (20) 10 (50.0) 14 (46.6) 25 (35.7)
Education≥ university 3 (15.0) 4 (20.0) 7 (23.3) 14 (20.0)
Employmenta 12 (60.0) 6 (30.0) 20 (68.9) 48 (69.6)
Current smoker 12 (60.0) 7 (35.0) 15 (50.0) 34 (48.6)
Alcohol last month 15 (75.0) 5 (25.0) 13 (44.8) 33 (47.8)
Past history of Injecting drugs 17 (85.0) 3 (15.8) 14 (48.3) 34 (50.0)
Treatmentb
Past history 5 (26.3) 2 (10.0) 17 (58.6) 24 (35.3)
Current 14 (70.0) 15 (75.0) 13c (46.4) 42 (61.8)
Pill burden (total number) 8.1 (6.3) 8.2 (4.8) 9.0 (5.4) 8.5 (5.4)
Antidepressant drugs 7 (35.0) 12 (60.0) 5 (16.7) 24 (34.3)
Antianxiety drugs 5 (20.0) 4 (20.0) 4 (13.3) 13 (18.6)
Sedative drugs 4 (20.0) 0 (0.0) 5 (17.9) 9 (13.4)
Clinical factors
Time since diagnosis (years) 5.0 (13.8) 3.5 (4.5) 8.0 (10.3) 5.0 (10.0)
HIV-Coinfection 5 (29.4) 5 (27.8) 4 (26.8) 14 (28.0)
Depression, self-reported (past month) 11 (55.0) 10 (50.0) 12 (41.4) 33 (47.8)
Symptoms (total number) 12.0 (7.0) 15.0 (13.5) 12.5 (6.0) 13.0 (7.0)
aInclusive of full time and part time work; bBoth interferon alpha and pegylated in combination with ribavirin; c8 patients (32 %) receiving directly acting
antiviral drugs
Data are summarised as count (percentage) for categorical variables, and mean (SD) for numerical variables
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necessarily indicate a longer duration of infection. In
France and Brazil approximately half of participants
were living with a partner and children in contrast with
Australians who more commonly lived alone. The French
and Australians were more likely to be employed, al-
though 40–70 % of participants reported not working at
all. According to the measure used to assess perceptions
of social status [28] most of the participants ranked them-
selves just less than half way between people of lowest and
highest status in society. Smoking and alcohol rates were
higher in Australians. Participants (62 %) were receiving
antiviral drugs, mostly combination interferon and ribavi-
rin, and 8 French patients were treated with directly acting
antivirals. Five additional interviews (not presented in
Table 1) were conducted with French patients on IFN-free
regimens. Ten patients were receiving treatment for both
depression and anxiety (15 %). The most frequently re-
ported symptoms were: fatigue, headache and dry skin.
Those on treatment were more likely to complain of
flu-like symptoms and loss of appetite (chi square test;
p = 0.012; p = 0.034) and people reporting depression
(n = 33) were more likely to complain of impaired
memory and concentration; and changes in olfactory
perception (p = 0.029; p = 0.027, p = 0.019). Symptom dis-
comfort (rated 0 to 3) was higher for the untreated group
for dental (p = .032) and sleep problems (p = .025), and
higher for people reporting depression for fatigue (p = .003)
and dental problems (p = .017) but lower for changes in ol-
factory perception (p = .002) (Fig. 2a-b).
Thematic analysis
Analysis of interview data revealed 29 themes constitut-
ing hepatitis C-specific health-related quality of life in
the context of both chronic infection and treatment
conditions. These were parcelled into 15 dimensions
representing the three overarching domains of Physical
Health, Mental Health, Social Health, and a fourth do-
main, HCV Treatment, that is new to this study. These
themes, dimensions and domains constitute our concep-
tual model of HCV HRQL (Fig. 3), and accord with pre-
vailing HRQL theory [29].
Physical Health incorporated fatigue, pain, sleep and
sexual impairment and physical activity; Mental Health
included psychological distress, psychosocial impact, and
cognition; Social Health incorporated support, activity,
stigma, and substance use. The impact of some dimen-
sions extended beyond their primary domains to affect
others including sleep and sexual function, concentra-
tion, memory and treatment burden. The fourth domain
assigned as ‘Treatment’ had influence on aspects of the
three other domains with respect to treatment adher-
ence, side effects, and treatment failure fears.
1. Physical Health: The pain dimension incorporated
themes of pain intensity and frequency and the
extent it interfered with physical, mental and social
activities. Pain was manifested by musculoskeletal
discomfort, morning stiffness, and ‘all over pain’.
Fatigue was framed by disrupted physical, mental
Fig. 2 a Symptoms by current HCV antiviral treatment status: Not treated O ; Treated Δ. Symptom discomfort range 0 = Not at all to 3 = Very
discomforting. b Symptoms by self-reported depression status: Not depressed O ; Depressed Δ. Symptom discomfort range 0 = Not at all to
3 = Very discomforting
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and social activity. Participants described chronic
low to medium intensity fatigue with debilitating,
sporadic high intensity episodes typically occurring
after injection of interferon. Physical activity was
constrained by health fluctuations that disrupted
routines and planned activities. The need for rest
limited mobility and travel distances and resulted in
a greater reliance on others, especially family
members, to carry out daily tasks. It was perceived
that partners underappreciated the intensity of
fatigue. A waning capacity for activity was
accompanied by a diminution of interests. The sleep
Fig. 3 Conceptual model of HCV-specific health-related quality of life
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dimension incorporated difficulties falling or remaining
asleep, and disturbances arising from anxiety, pain and
itching which effected alertness the next day.
Depressive and treatment-related symptoms and
contagion/transmission anxieties resulted in negative
impacts on sexuality, including reduced libido,
difficulty maintaining arousal and achieving orgasm.
2. Mental Health: Depression, anxiety, stress and
struggles associated with antiviral treatment resulted
in distress. Participants described shock, disbelief,
grief, frustration, and helplessness. Feelings of
nervousness, heightened irritability, anger and rage
were disturbing and unexpected. Participants were
concerned their infections might be incurable and
felt a loss of control and independence. Some
viewed their futures to be bleak and in some cases
were fearful of dying – especially those who were
parents; and emotional distress disrupted
relationships.
Positive and negative psychosocial impacts reflecting
adjustments to HCV-associated emotional reactions
were described. Mental health-related changes
resulted in an altered self-perception and expression
of personality. Appreciation of life was re-appraised
and goals adjusted, and some described a greater
respect and empathy for others. Behavioural changes
in health-seeking practices were related to diet,
exercise, usage of complementary therapies and
altered hygiene routines. Cognitive and behavioural
strategies included: positive thinking, for example,
that side effects of medication were part of the
healing process, determination to complete the
treatment course, meditation and prayer. Problems
with concentration and memory interfered with
maintaining schedules, locating essential tools and
completing sequential steps in a task. Cognition was
disrupted by sleep disturbances and fatigue.
3. Social Health: Encompassed the sense of being
cared for by family and friends; and professional and
informational support. Some participants described
losing social invitations, companionship and marital/
relational instability but others described feeling
cared for and valued. Regular engagement with
health professionals supported confidence, sense of
control and medication adherence. Loss of social
activity drew together, thematically, the interest,
accessibility, capacity and satisfaction with typical
daily social activity following a diagnosis of HCV.
Opportunities to participate in group sporting
activities due to infectivity, and avoidance of drugs
and alcohol, limited social interaction as did limited
energy and a sense of lost attractiveness. HCV-related
stigma infused the Social Health domain and
influenced personal and social identity. Self was
perceived as ‘diseased’ and there was a fear of
disclosing HCV sero-status and transmitting the
infection. In addition, discrimination in healthcare
settings, the workplace, and from family and
friends was evidenced. Stigma concerns often
resulted in socially avoidant behaviour.
The use of substances was characterised by positive
and negative statements related to coping with
reduced substance use leading to better health but
also the loss of socialisation with friends connected
through the use of drugs and alcohol. Some failed to
cope with the abstinence required for treatment
eligibility and struggled to overcome substance
dependency.
4. Treatment: Treatment impacted the Physical,
Mental and Social domains of HRQL in complex
ways. Participants undergoing hepatitis treatment
were required to make life adjustments for the
duration of therapy. Regimen adherence was
described as a ‘responsibility’ which restricted travel
and required concealment. Prior to treatment there
was fear of side effects and treatment inefficacy.
Side-effects including changes in appearance like
weight loss, jaundice and hair loss affected self-
esteem and sense of social acceptability sometimes
resulting in treatment cessation (or interruption).
Other participants felt ready to cope and some with
the means to do so, made plans to withdraw socially
and/or from employment to complete treatment.
Determination was evident with hopes of longevity
promoting persistence with treatment, others were
anxious about treatment failure or recurrent
infection. Side effects that impacted mood were
troublesome, including aggression and irritability,
sexual function, personal appearance and
interruptions to travel plans. In stark contrast with
people taking interferon, those treated with DAAs
reported feelings of cheerfulness, approaching
euphoria, and were reluctant to stop their treatment.
Thematic differences based on country of origin
While the interview data mostly revealed commonalities in
health-related quality of life matters between participants
from the three countries, some differences emerged. Brazil-
ian interviewees were more likely to identify their health as
concerning their families. They were more likely to live in
shared spaces with family and non-family members and ex-
press concern around interpersonal hygiene. In contrast
participants from French and Australian cultures were
more likely to identify their health as a self-concern rather
than a family concern and more often lived alone or in cou-
ples. French interviewees emphasised their fears for the fu-
ture more than other participants. Australian interviewees
commonly reported ceasing employment and reducing
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their level of social engagement for the period of treatment
whereas participants from Brazil and France did not. Prac-
ticing religion and prayer helped many of the Brazilian in-
terviewees to cope whereas other participants very rarely
raised this.
Discussion
We developed a conceptual model and pilot survey instru-
ment of HCV-specific HRQL in-line with US Federal
Drug Administrion (FDA), and European Medicines
Agency (EMA) guidelines [25, 30]. The model and instru-
ment incorporate three broad HRQL domains of Physical,
Mental and Social Health, and a fourth – Treatment - that
captures patient experience with interferon-based and
interferon free regimens. The model and pilot instrument
embody the breadth of issues impacting the quality of life
of people affected by hepatitis C and clearly demonstrate
content validity. Other HRQL instruments identify and
elucidate one or more of these themes, but do not unify
them within a comprehensive HCV-specific HRQL model.
This may reflect of a lack of heterogeneity in the samples
during the instruments’ development which undermines
their content validity.
In contrast we collated an item bank from a qualitative
sample reflecting demographic diversity in terms of dis-
ease stage, treatment status, sex, linguistic, educational
and healthcare contexts. Furthermore, subsumed within
our dimensions, are disease-nuanced items tapping im-
portant issues not incorporated in other instruments.
For instance, while distress is a common element of
HRQL measurement, our model identifies HCV-specific
distress arising from: contagiousness concerns, guilt and
worry about impact on family, fear of complications, un-
certainty, around the trajectory of the illness, emotional
volatility and irritability. Likewise, subjectively experi-
enced deficits in attention, concentration and memory
that impact on quality of life are included and can pro-
vide additional information to objective performance
tests. Our instrument incorporates sexual function as
does other HRQL instruments, but importantly discrimi-
nates dysfunction from reduced sex drive, problems with
sustaining arousal, or stigma affecting partner availabil-
ity. Few HCV-HRQL instruments capture internalised
stigma, i.e. a sense of ‘self ’ as contagious, in additional
to interpersonal fears of social rejection.
We sought to address the cultural nuances that emerged
by finding common threads across the Brazilian, French
and Australian interviews. We adapted item formulation
to retain the same content meanings across the three lan-
guages with the intention of strengthening and enhancing
the content validity of the items.
Our conceptual model incorporates the impact of
treatment into HRQL assessment. This is novel. This in-
strument was developed in the context of chronic
infection, HIV co-infection and changing treatment
strategies. Identifying fluctuation or changes in HRQL in
response to interventions is critical to effective monitor-
ing of patient outcomes and PROQOL-HCV captures
these nuances.
Psychometric assessment, refinement and validation of
the pilot PROQOL HCV survey instrument is currently
underway. It has been administrated to samples of HCV
patients in France, Brazil and Australia. We intend to
publish a short version of the survey for use in large
multi-focus studies where space is limited, and a long
version for use in more focused HCV HRQL investiga-
tions, as we have done for HIV HRQL research [31].
We acknowledge limitations. A degree of subjectivity
was inevitable in the identification and extraction of
interview themes and other researchers may have pro-
posed a different nomenclature for the themes or their
dimensional arrangement but the development of the
instrument was evidence-based and consensus driven.
PROQOL-HCV is a disease-specific instrument and is
therefore limited in application to the management of
hepatitis C.
The decision to conduct this study in Brazil, France
and Australia was to an extent pragmatic since the
teams had collaborated successfully in the past and
therefore we were confident that the project could be
implemented feasibly in these countries. However, there
are features of the epidemic and access to treatment that
are informative across the regions. Furthermore, previ-
ous experience with large international studies had led
us to the observation that development of HRQL in a
single country is not satisfactory. However including too
many countries in the simultaneous development would
prolong the development process unnecessarily. Our ap-
proach also meant that idiomatic expression and other
difficulties of expression and meaning could be resolved
during the item generation phase and our pilot instru-
ment would be the more robust because of this. It is the
case that linguistic validation/cultural adaptation will be
needed for countries not speaking French, English or
Portuguese but this method had been used for many
other instruments.
Conclusion
Potent anti-viral alternatives to IFN and ribavirin have
improved the possibility of achieving a sustained viro-
logical clearance. The arrival of new treatments, with
comparably high effectiveness, low toxicity and high
prices, call for using disease-sensitive HRQL measures
to support decisions regarding treatment choice. Suc-
cessful treatment limits liver-related morbidity and in-
creases health related quality of life [32]. However,
mathematical modelling suggests that HCV is under-
diagnosed, people with existing infections are numerous
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and that better clinical management of infected people is
required [33]. Given the evident HRQL impacts of
HCV we recommend embedding monitoring of
patient-reported outcomes in clinical care. PROQOL-
HCV, derived from our HCV-specific conceptual
model, shows promise as a comprehensive and dis-
criminating PRO instrument sensitive to the full
range of disease and treatment experiences of HCV
patients, clearly distinguishing it from existing HRQL
measures.
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